about
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech populationDynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.Molecular cytogenetic analysis of dicentric chromosomes in acute myeloid leukemia.Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5.5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation.Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms.Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.Nature of frequent deletions in CEBPA.Characterization of chromosome 11 breakpoints and the areas of deletion and amplification in patients with newly diagnosed acute myeloid leukemia.Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites.Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients.A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.Differential expression of homologous recombination DNA repair genes in the early and advanced stages of myelodysplastic syndrome.NQO1*2 polymorphism predicts overall survival in MDS patients.Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.Involvement of deleted chromosome 5 in complex chromosomal aberrations in newly diagnosed myelodysplastic syndromes (MDS) is correlated with extremely adverse prognosisDeletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignanciesThrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q− MDS (IPSS low and intermediate-1)High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomideCyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrowEffect of erythropoietin on hepcidin expression in hemojuvelin-mutant miceDefective cytotoxicity of T lymphocytes in myelodysplastic syndromeEfficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome
P50
Q33433485-B2CF9D25-0FB6-4CC1-BC91-C43799AC0558Q36565137-EA746A21-740C-4173-87A1-36F7ECDE48BEQ37380379-C3ED2B88-7BB1-43A3-A146-EA152EB7C8F5Q37392696-D6FAF47B-9B0A-4C30-89C7-74C28B65465EQ38798626-711CB7A6-F86F-449B-B157-17A0F5A7FA72Q39026960-3864ADC1-345C-40F1-A2F3-CDE09D8CBEF6Q39395000-2ED7610D-457F-439A-A92E-0F022500E70EQ39592066-234CB0AA-842E-4AB9-BB11-8DA7364791ECQ39601934-0C2237FD-E299-439A-9DE8-8D49AC183730Q40018345-A46DB6A6-B802-4BC2-ABFC-6C55ED61B693Q40911142-900386AD-05DA-415D-AADC-19F2202669ACQ41060122-3F7B5475-95E9-481B-8D97-C3D1345EA6B1Q43299358-575F6841-ED5E-4D6E-B18D-A0F6BB28F0CFQ43410945-8A47BDC9-1F4D-4063-A036-5C4849CD4F77Q43475554-844F898A-16FB-4A5F-947B-6D25EB3FE1FDQ43984339-BCF8400D-5B92-4E10-8330-B9133C17C1CEQ46095097-94F9C529-2DA0-41EC-9823-AC6386D27E93Q46364652-692198EE-74C2-4C02-B19E-A94DDF1A5172Q46513684-F6E86151-3EFC-4188-9DC9-ECAB76F33367Q47769358-0F1CA2F2-9227-4BC1-9405-11DA46B2E916Q47796352-2CA9A257-0514-4413-BFE8-145D92993910Q48169044-34D050A4-36E8-4CCD-AD57-1075D3302971Q48177010-AB8C0556-F8CD-4D48-A84D-CC2478C19AAEQ53423040-F51BC5CE-5DF4-4B59-93AB-6864044C588FQ58459149-12EC12FC-3537-4E74-9C28-AD4300F39F80Q58459187-AF4F6135-0483-4E4E-A3A9-2A828C5D59E1Q58459207-03F78033-1AAB-4549-B817-7F218E6EEADDQ61074019-AD6BAA98-651C-4807-BC5A-688E9269A4DEQ74263466-B2030948-153A-421E-B819-9B087246D689Q83169473-304C0EA5-1F8F-47B0-84B7-ACA33BD21BD6Q83171714-1FA611A2-FAC7-4837-A6C3-02E093B4AB96Q84156924-AC0A6078-D087-4895-926D-DBEB1FE661C3
P50
description
researcher, ORCID id # 0000-0003-0246-1524
@en
wetenschapper
@nl
name
Anna Jonasova
@ast
Anna Jonasova
@en
Anna Jonasova
@es
Anna Jonasova
@nl
type
label
Anna Jonasova
@ast
Anna Jonasova
@en
Anna Jonasova
@es
Anna Jonasova
@nl
prefLabel
Anna Jonasova
@ast
Anna Jonasova
@en
Anna Jonasova
@es
Anna Jonasova
@nl
P1153
6602336000
P21
P31
P496
0000-0003-0246-1524